PH12019500758A1 - Pharmaceutical compositions and methods for the treatment of cancer - Google Patents

Pharmaceutical compositions and methods for the treatment of cancer

Info

Publication number
PH12019500758A1
PH12019500758A1 PH12019500758A PH12019500758A PH12019500758A1 PH 12019500758 A1 PH12019500758 A1 PH 12019500758A1 PH 12019500758 A PH12019500758 A PH 12019500758A PH 12019500758 A PH12019500758 A PH 12019500758A PH 12019500758 A1 PH12019500758 A1 PH 12019500758A1
Authority
PH
Philippines
Prior art keywords
promoter
methods
subject
pharmaceutical compositions
inhibitor
Prior art date
Application number
PH12019500758A
Inventor
Steven Hoffman
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/351,966 external-priority patent/US10272068B2/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of PH12019500758A1 publication Critical patent/PH12019500758A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
PH12019500758A 2016-11-15 2019-04-08 Pharmaceutical compositions and methods for the treatment of cancer PH12019500758A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/351,966 US10272068B2 (en) 2012-01-17 2016-11-15 Pharmaceutical compositions and methods
PCT/US2017/061682 WO2018093820A1 (en) 2016-11-15 2017-11-15 Pharmaceutical compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
PH12019500758A1 true PH12019500758A1 (en) 2019-07-24

Family

ID=60570232

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019500758A PH12019500758A1 (en) 2016-11-15 2019-04-08 Pharmaceutical compositions and methods for the treatment of cancer

Country Status (12)

Country Link
EP (1) EP3541411A1 (en)
JP (2) JP2019537608A (en)
KR (2) KR20190084291A (en)
CN (1) CN110167580A (en)
AU (1) AU2017361080A1 (en)
BR (1) BR112019009799A2 (en)
CA (1) CA3040922A1 (en)
EA (1) EA201991192A1 (en)
IL (1) IL266486A (en)
MX (1) MX2019005450A (en)
PH (1) PH12019500758A1 (en)
WO (1) WO2018093820A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114173578A (en) 2019-05-14 2022-03-11 迪美公司 Compositions and methods for treating cancer
US20210106549A1 (en) * 2019-10-15 2021-04-15 Tyme, Inc. Pharmaceutical compositions and methods
EP4090329A2 (en) * 2020-01-17 2022-11-23 Tyme, Inc. Tyrosine derivatives for modulating cancer
CN111358777A (en) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 Method for improving mitochondrial function of peripheral blood mononuclear cells and application
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
US8481498B1 (en) * 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
EP3488848A1 (en) * 2012-01-17 2019-05-29 Tyme, Inc. Tyrosine hydroxylase inhibitors for use in treating cancer
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
EA201991192A1 (en) 2019-10-31
BR112019009799A2 (en) 2019-08-06
KR20230003314A (en) 2023-01-05
JP2019537608A (en) 2019-12-26
MX2019005450A (en) 2019-07-04
CA3040922A1 (en) 2018-05-24
EP3541411A1 (en) 2019-09-25
IL266486A (en) 2019-07-31
KR20190084291A (en) 2019-07-16
AU2017361080A1 (en) 2019-05-02
JP2023018029A (en) 2023-02-07
CN110167580A (en) 2019-08-23
WO2018093820A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
PH12014501639A1 (en) Pharmaceutical compositions and methods
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020013649A (en) Compositions and methods for inhibiting arginase activity.
MX2022005216A (en) Pyridazinones as parp7 inhibitors.
EA201890961A1 (en) COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT NORROFORMATION
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
MX2021006734A (en) Method for treating cancer.
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
BR112018007656A2 (en) combination therapy for treatment of malignant diseases
MX2018007266A (en) Combinations for the treatment of cancer.
MX2020001727A (en) Combination therapy.
MX2019013862A (en) Combination therapy.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
MX2017011018A (en) Inhibition of olig2 activity.
MX2021012418A (en) Heterocyclic compounds and uses thereof.
ZA201901367B (en) Inhibition of olig2 activity
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
MX2021002818A (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k).
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.
MX2020012782A (en) Ccr5 inhibitor for use in treating cancer.
MX2019001337A (en) Methods of treating and preventing cancer treatment side effects.
MX2022005250A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies.